Most native peptides are cleared in minutes, and almost every engineered peptide in a research catalogue exists because somebody solved that. There are only a handful of ways to extend a peptide's half-life, they are used in combination, and each one leaves a signature in the sequence. Recognising the signature tells you what the molecule was designed to survive.
Why native peptides disappear so quickly
Three routes, running at once. Enzymatic cleavage: exopeptidases chew inward from the ends and endopeptidases cut internally, and specific enzymes target specific motifs — dipeptidyl peptidase-4 cleaves after the second residue when that residue is alanine or proline. Renal filtration: the glomerulus passes molecules below roughly 60 kDa, and essentially every peptide is far below that. Receptor-mediated clearance: binding a receptor and being internalised removes the molecule along with the signal.
The strategies below address these in different places, which is why they combine rather than compete.
The four strategies
| Strategy | What it defeats | Signature in the molecule |
|---|---|---|
| Residue substitution | A specific protease | Aib, D-amino acids, non-natural residues |
| Terminal modification | Exopeptidases | N-acetylation, C-amidation, Pro-Gly-Pro tails |
| Albumin binding | Renal filtration | A fatty acid chain on a lysine side chain |
| Size increase | Renal filtration | PEG chains, Fc fusion |
Why does swapping one residue make such a difference?
Because proteases are specific, and defeating one of them removes a whole clearance route rather than slowing it. Replacing the alanine at position two with 2-aminoisobutyric acid — a residue with an extra methyl group that no ribosome uses — means DPP-4 no longer recognises the site. The molecule is otherwise almost unchanged, and its stability goes from minutes to hours. A single non-natural residue at a cleavage site is the highest-leverage change available, which is why it appears throughout the incretin class.
What does acylation actually do?
It borrows albumin's half-life. A fatty acid chain, usually attached to a lysine side chain through a linker, binds reversibly to serum albumin — a protein far too large to be filtered by the kidney. The peptide is therefore held in circulation as a reservoir, in equilibrium with a small free fraction that remains available to act. Half-life moves from hours to days. The three incretin-family compounds in the catalogue all rely on it.
The cost is that the molecule is now amphipathic. Acylated peptides concentrate at air–liquid interfaces, foam readily if shaken, and bind hydrophobic plastics — so adsorption losses are a practical concern rather than a theoretical one, and low-binding tubes matter more than they would for an unmodified sequence.
Is the DAC on CJC-1295 the same idea as acylation?
Same goal, different chemistry, and the difference matters. Acylation binds albumin non-covalently through a fatty acid; the Drug Affinity Complex carries a reactive maleimide group that forms a covalent bond with a free thiol on albumin. Non-covalent binding is reversible and in equilibrium; covalent attachment is not. That is why the two versions sold under one name behave so differently — CJC-1295 with and without DAC are different molecules, with half-lives separated by orders of magnitude, and a citation naming only the code is ambiguous about which was studied.
What terminal modifications do
Exopeptidases need a free terminus to work on. Blocking one removes that handle.
C-terminal amidation replaces the terminal carboxyl with an amide. It removes a negative charge, adds resistance to carboxypeptidases, and for many sequences it is also what the native hormone looks like — a considerable number of signalling peptides are amidated in vivo, so the modification restores the natural form rather than inventing one.
N-terminal acetylation caps the free amino group against aminopeptidases.
Proline-rich tails work differently: rather than capping, they present a backbone geometry most peptidases cannot accommodate. The Pro-Gly-Pro extension on Selank and Semax is the clearest example, and it is why two unrelated fragments ended up looking like relatives.
Does a longer half-life make a compound better?
Only relative to a purpose. A long half-life means sustained exposure and less frequent handling; it also means the exposure cannot be stopped quickly once it has begun, and that anything unwanted persists as long as anything wanted. In an experiment, a short half-life is sometimes precisely the property being used — a pulse is a different stimulus from a plateau, and for anything studying pulsatile signalling the short-acting form is the correct tool and the long-acting one is the wrong one. Sermorelin and tesamorelin sit in that comparison.
Why can half-life figures not be compared between sources?
Because the number depends on the species, the route, the assay and what counts as the molecule. A half-life measured in rodents is routinely shorter than in humans for the same compound, since clearance scales with body size. An assay detecting total compound reports a longer figure than one detecting only the free fraction — and for an albumin-bound peptide those two differ enormously. Terminal and effective half-life are different quantities. A figure quoted without its species, method and definition is not comparable to another figure quoted the same way, which is a general problem with catalogue specifications rather than a fault of any one source.
Do these modifications show up on a certificate?
In the identity panel, if you read the mass rather than the name. Every modification changes the molecular weight: amidation by about one unit, acetylation by 42, an acylation chain by several hundred. A theoretical mass calculated from the bare sequence will not match a modified peptide, and the discrepancy is the modification rather than an error. Knowing which panel answers which question is what makes that difference readable instead of alarming.
All products referenced here are supplied for laboratory and research use only. They are not drugs, foods, supplements or cosmetics, and are not for human or veterinary use.
